|
1
|
Joly-Guillou ML: Clinical impact and
pathogenicity of Acinetobacter. Clin Microbiol Infect. 11:868–873.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wong D, Nielsen TB, Bonomo RA,
Pantapalangkoor P, Luna B and Spellberg B: Clinical and
pathophysiological overview of acinetobacter infections: A century
of challenges. Clin Microbiol Rev. 30:409–447. 2017.PubMed/NCBI
|
|
3
|
Cai Y, Chai D, Wang R, Liang B and Bai N:
Colistin resistance of Acinetobacter baumannii: Clinical reports,
mechanisms and antimicrobial strategies. J Antimicrob Chemother.
67:1607–1615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Novovic K, Mihajlovic S, Vasiljevic Z,
Filipic B, Begovic J and Jovcic B: Carbapenem-resistant
Acinetobacter baumannii from Serbia: Revision of CarO
classification. PLoS One. 10:e01227932015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boulanger A, Naas T, Fortineau N,
Figueiredo S and Nordmann P: NDM-1-producing Acinetobacter
baumannii from Algeria. Antimicrob Agents Chemother. 56:2214–2215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Revathi G, Siu LK, Lu PL and Huang LY:
First report of NDM-1-producing Acinetobacter baumannii in East
Africa. Int J Infect Dis. 17:e1255–e1258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones LS, Toleman MA, Weeks JL, Howe RA,
Walsh TR and Kumarasamy KK: Plasmid carriage of bla NDM-1 in
clinical Acinetobacter baumannii isolates from India. Antimicrob
Agents Chemother. 58:4211–4213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Gamal MI, Brahim I, Hisham N, Aladdin
R, Mohammed H and Bahaaeldin A: Recent updates of carbapenem
antibiotics. Eur J Med Chem. 131:185–195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McGuinness WA, Malachowa N and DeLeo FR:
Vancomycin resistance in Staphylococcus aureus. Yale J Biol
Med. 90:269–281. 2017.PubMed/NCBI
|
|
10
|
Acar JF, Goldstein FW and Kitzis MD:
Susceptibility survey of piperacillin alone and in the presence of
tazobactam. J Antimicrob Chemother. 31 (Suppl A):S23–S28. 1993.
View Article : Google Scholar
|
|
11
|
Sörgel F and Kinzig M: The chemistry,
pharmacokinetics and tissue distribution of
piperacillin/tazobactam. J Antimicrob Chemother. 31 (Suppl
A):S39–S60. 1993. View Article : Google Scholar
|
|
12
|
Joly-Guillou ML, Decré D, Herrman JL,
Bourdelier E and Bergogne-Bérézin E: Bactericidal in-vitro activity
of beta-lactams and beta-lactamase inhibitors, alone or associated,
against clinical strains of Acinetobacter baumannii: Effect of
combination with aminoglycosides. J Antimicrob Chemother.
36:619–629. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Nation RL, Turnidge JD, Milne RW,
Coulthard K, Rayner CR and Paterson DL: Colistin: The re-emerging
antibiotic for multidrug-resistant Gram-negative bacterial
infections. Lancet Infect Dis. 6:589–601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arroyo LA, Herrera CM, Fernandez L,
Hankins JV, Trent MS and Hancock RE: The pmrCAB operon mediates
polymyxin resistance in Acinetobacter baumannii ATCC 17978 and
clinical isolates through phosphoethanolamine modification of lipid
A. Antimicrob Agents Chemother. 55:3743–3751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moffatt JH, Harper M, Harrison P, Hale JD,
Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, et
al: Colistin resistance in Acinetobacter baumannii is mediated by
complete loss of lipopolysaccharide production. Antimicrob Agents
Chemother. 54:4971–4977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kimberly CC, Anna DF and Michael JR: A
review of novel combinations of colistin and lipopeptide or
glycopeptide antibiotics for the treatment of multidrug-resistant
Acinetobacter baumannii. Infect Dis Ther. 3:69–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Patel J, Cockerill F, Bradford P,
Eliopoulos G, Hindler J, Jenkins S, Lewis J, Limbago B, Miller L,
Nicolau D, et al: Performance standards for antimicrobial
susceptibility testing: Twenty-fifth informational supplement;
M100-S25Wayne, PA: CLSI; 35. 2015
|
|
18
|
Clinical and Laboratory Standards
Institute, . Performance standards for antimicrobial susceptibility
testing; twenty-fifth informational supplement (M100-S25)Wayne
(PA): The Institute; 2015
|
|
19
|
Shoma S, Kamruzzaman M, Ginn AN, Iredell
JR and Partridge SR: Characterization of multidrug-resistant
Klebsiella pneumoniae from Australia carrying blaNDM-1.
Diagn Microbiol Infect Dis. 78:93–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rodriguez-Martinez JM, Nordmann P,
Fortineau N and Poirel L: VIM-19, a metallo-beta-lactamase with
increased carbapenemase activity from Escherichia coli and
Klebsiella pneumoniae. Antimicrob Agents Chemother.
54:471–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qin S, Fu Y, Zhang Q, Qi H, Wen JG, Xu H,
Xu L, Zeng L, Tian H, Rong L, et al: High incidence and endemic
spread of NDM-1-positive Enterobacteriaceae in Henan Province,
China. Antimicrob Agents Chemother. 58:4275–4282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo H and Xiong J: A specific and
versatile genome walking technique. Gene. 381:18–23. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li P, Yang C, Xie J, Liu N, Wang H, Zhang
L, Wang X, Wang Y, Qiu S and Song H: Acinetobacter calcoaceticus
from a fatal case of pneumonia harboring bla(NDM-1) on a widely
distributed plasmid. BMC Infect Dis. 15:1312015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pfeifer Y, Wilharm G, Zander E, Wichelhaus
TA, Göttig S, Hunfeld KP, Seifert H, Witte W and Higgins PG:
Molecular characterization of blaNDM-1 in an Acinetobacter
baumannii strain isolated in Germany in 2007. J Antimicrob
Chemother. 66:1998–2001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bartual SG, Seifert H, Hippler C, Luzon
MA, Wisplinghoff H and Rodriguez-Valera F: Development of a
multilocus sequence typing scheme for characterization of clinical
isolates of Acinetobacter baumannii. J Clin Microbiol.
43:4382–4390. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Memish ZA, Assiri A, Almasri M, Roshdy H,
Hathout H, Kaase M, Gatermann SG and Yezli S: Molecular
characterization of carbapenemase production among gram-negative
bacteria in saudi arabia. Microb Drug Resist. 21:307–314. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Poirel L, Héritier C, Tolün V and Nordmann
P: Emergence of oxacillinase-mediated resistance to imipenem in
Klebsiella pneumoniae. Antimicrob Agents Chemother.
48:15–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chatterjee S, Datta S, Roy S, Ramanan L,
Saha A, Viswanathan R, Som T and Basu S: Carbapenem resistance in
Acinetobacter baumannii and other acinetobacter spp. causing
neonatal sepsis: Focus on NDM-1 and its linkage to ISAba125. Front
Microbiol. 7:11262016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aaron SD, Ferris W, Henry DA, Speert DP
and Macdonald NE: Multiple combination bactericidal antibiotic
testing for patients with cystic fibrosis infected with
Burkholderia cepacia. Am J Respir Crit Care Med. 161:1206–1212.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aaron SD, Ferris W, Ramotar K, Vandemheen
K, Chan F and Saginur R: Single and combination antibiotic
susceptibilities of planktonic, adherent, and biofilm-grown
Pseudomonas aeruginosa isolates cultured from sputa of adults with
cystic fibrosis. J Clin Microbiol. 40:4172–4179. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Percin D, Akyol S and Kalin G: In vitro
synergism of combinations of colistin with selected antibiotics
against colistin-resistant Acinetobacter baumannii. GMS Hyg Infect
Control. 9:Doc142014.PubMed/NCBI
|
|
32
|
Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ,
Lu CL and Chuang YC: In vitro and in vivo activity of meropenem and
sulbactam against a multidrug-resistant Acinetobacter baumannii
strain. J Antimicrob Chemother. 53:393–395. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Abbo A, Navon-Venezia S, Hammer-Muntz O,
Krichali T, Siegman-Igra Y and Carmeli Y: Multidrug-resistant
Acinetobacter baumannii. Emerg Infect Dis. 11:22–29. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nordmann P, Poirel L, Toleman MA and Walsh
TR: Does broad-spectrum beta-lactam resistance due to NDM-1 herald
the end of the antibiotic era for treatment of infections caused by
Gram-negative bacteria? J Antimicrob Chemother. 66:689–692. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, Zhou Z, Jiang Y and Yu Y:
Emergence of NDM-1-producing Acinetobacter baumannii in China. J
Antimicrob Chemother. 66:1255–1259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou Z, Guan R, Yang Y, Chen L, Fu J, Deng
Q, Xie Y, Huang Y, Wang J, Wang D, et al: Identification of New
Delhi metallo-β-lactamase gene (NDM-1) from a clinical isolate of
Acinetobacter junii in China. Can J Microbiol. 58:112–115. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tran DN, Tran HH, Matsui M, Suzuki M,
Suzuki S, Shibayama K, Pham TD, Van Phuong TT, Dang DA, Trinh HS,
et al: Emergence of New Delhi metallo-beta-lactamase 1 and other
carbapenemase-producing Acinetobacter calcoaceticus-baumannii
complex among patients in hospitals in Ha Noi, Viet Nam. Eur J Clin
Microbiol Infect Dis. 36:219–225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Poirel L, Bonnin RA, Boulanger A,
Schrenzel J, Kaase M and Nordmann P: Tn125-related acquisition of
blaNDM-like genes in Acinetobacter baumannii. Antimicrob Agents
Chemother. 56:1087–1089. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Karaiskos I and Giamarellou H:
Multidrug-resistant and extensively drug-resistant Gram-negative
pathogens: Current and emerging therapeutic approaches. Expert Opin
Pharmacother. 15:1351–1370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tamma PD, Cosgrove SE and Maragakis LL:
Combination therapy for treatment of infections with gram-negative
bacteria. Clin Microbiol Rev. 25:450–470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marques MB, Brookings ES, Moser SA, Sonke
PB and Waites KB: Comparative in vitro antimicrobial
susceptibilities of nosocomial isolates of Acinetobacter baumannii
and synergistic activities of nine antimicrobial combinations.
Antimicrob Agents Chemother. 41:881–885. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rodríguez-Hernández MJ, Pachón J, Pichardo
C, Cuberos L, Ibáñez-Martínez J, García-Curiel A, Caballero FJ,
Moreno I and Jiménez-Mejías ME: Imipenem, doxycycline and amikacin
in monotherapy and in combination in Acinetobacter baumannii
experimental pneumonia. J Antimicrob Chemother. 45:493–501. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wolff M, Joly-Guillou ML, Farinotti R and
Carbon C: In vivo efficacies of combinations of beta-lactams,
beta-lactamase inhibitors, and rifampin against Acinetobacter
baumannii in a mouse pneumonia model. Antimicrob Agents Chemother.
44:1406–1411. 1999. View Article : Google Scholar
|
|
44
|
Gordon NC, Png K and Wareham DW: Potent
synergy and sustained bactericidal activity of a
vancomycin-colistin combination versus multidrug-resistant strains
of Acinetobacter baumannii. Antimicrob Agents Chemother.
54:5316–5322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Levin AS: Multiresistant Acinetobacter
infections: A role for sulbactam combinations in overcoming an
emerging worldwide problem. Clin Microbiol Infect. 8:144–153. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kempf M, Djouhri-Bouktab L, Brunel JM,
Raoult D and Rolain JM: Synergistic activity of sulbactam combined
with colistin against colistin-resistant Acinetobacter baumannii.
Int J Antimicrob Agents. 39:180–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
